Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imetelstat in High-Risk MDS or AML After HMA Failure
2022-500721-32-00Phase 2Withdrawn
- Sponsor
- GCP-Service International
- Start
- Jan 2023
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of imetelstat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by GCP-Service International. Primary endpoint: Overall response rate at 4 months. Planned start Jan 2023; status: withdrawn.
02
Drugs
imetelstat
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2022-500721-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500721-32-00.